Who
Derek M. Meisner
Chief Legal Officer & Corp Sec
Company insider
Files Form 4 as: Chief Legal Officer & Corp Sec, Acumen Pharmaceuticals; Chief Legal Officer, X4 Pharmaceuticals; Senior VP and General Counsel, Genocea Biosciences.
In numbers
- Trades disclosed
- 79
- Buys
- 0
- Sells
- 24
- Bought
- $0
- Sold
- $726K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 20 Sep 2018
- Last trade
- 6 Mar 2026
- Last filed
- 10 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Mar 2026filed 10 Mar 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $3,8672,090 at $1.85 | filing |
| 6 Mar 2026filed 10 Mar 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $6,8132,090 at $3.26 | filing |
| 6 Mar 2026filed 10 Mar 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,090 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,090 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $3,8672,090 at $1.85 | filing |
| 6 Mar 2026filed 10 Mar 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $6,8132,090 at $3.26 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $17K9,406 at $1.85 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $28K9,406 at $3.01 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,406 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,406 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $17K9,406 at $1.85 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $28K9,406 at $3.01 | filing |
| 28 Jan 2026filed 28 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $4,9412,671 at $1.85 | filing |
| 28 Jan 2026filed 28 Jan 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,671 at $0.00 | filing |
| 28 Jan 2026filed 28 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $8,0172,671 at $3.00 | filing |
| 28 Jan 2026filed 28 Jan 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,671 at $0.00 | filing |
| 28 Jan 2026filed 28 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $4,9412,671 at $1.85 | filing |
| 28 Jan 2026filed 28 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $8,0132,671 at $3.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $28K15,085 at $1.85 | filing |
| 26 Jan 2026filed 28 Jan 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $45K15,085 at $3.00 | filing |
News
No headline names them, or the companies they trade most, lately.